Myopia management refers to the methods an ECP uses to slow the growth of the eye, thus slowing the progression of myopia in children. By starting myopia management early, ECPs have a better chance of preventing eye diseases and conditions in the child’s future.
However, patients may not realize that the myopia management solutions you offer are based on research. At HOYA Canada, we’ve specialized in myopia management for many years –having extensively studied and researched this condition so we could bring you, the ECP, a proven solution for myopic patients.
3 ways clinical evidence makes myopia management easier
A myopia management solution with a robust and wide spectrum of evidence could empower you to meet the needs of diverse patients, with confidence.
1. How evidence builds confidence for patients
As we are dealing with children and the critical treatment time is often a few years, myopic children need treatment solutions that are clinically proven, and the parents want the best for their children.
When patients visit their local ECP, they’re looking for someone they can trust and who can answer their pressing questions about conditions like myopia. An eye care professional who prescribes based on research and data leads to patient confidence, satisfaction, and loyalty.
2. How evidence builds confidence for professionals
Proving the effectiveness of a myopia management solution is not a simple task. It has a long observation time; it takes months to see the results of a myopia management solution and years to evaluate if its treatment effect is sustained and if there is a possibility of rebound effect.
It’s not easy for ECPs to evaluate the myopia management effect of a lens by testing it on a small group of patients. First, they may have a huge variation of individual patients, and those patients come with many compounding factors such as age, lifestyle, and compliance.
Robust evidence brings ECPs more assurance and confidence when prescribing a myopia management solution.
- Evidence from peer-reviewed published studies could alleviate the pressure from ECPs when making clinical decisions
- This research assists and informs conversations with patients who are parents
- Being savvy with clinical data supports the ECP in becoming an expert and trusted professional
3. How evidence builds up your practice
Embracing myopia management brings enhanced patient loyalty, increased practice revenue, and improved job satisfaction because:
- Results speak for themselves, driving practice validity
- One happy myopic patient could bring the whole family
- There is power in word-of-mouth among the parent community
- Your staff is able to point to data-supported solutions
Not all evidence is of equal quality and strength
Clinical studies evaluate the performance and safety of the treatment solution, but they also aim to answer your questions in everyday practice and instill confidence. However, not all evidence is equal. Different studies carry more strength than others, so It's important to differentiate between them.
First, consider if the study was published in a credible, peer-reviewed scientific journal for reliable and trustworthy information. Assess how robust the evidence is and how it can inform your practice. Evidence should be able to answer your clinical questions, leaving you with confidence when making treatment decisions.
How does clinical evidence of MiYOSMART spectacle lenses answer your clinical questions?
MiYOSMART is HOYA’s evidence-based, non-invasive method to manage myopia. It was designed to slow down the progression of myopia in myopic children and adolescents. It has been clinically proven to do this by an average of 60%.
MiYOSMART’s evidence aims to answer all your clinical questions, so you can confidently manage myopia in your everyday practice.
- The DIMS Technology used in MiYOSMART spectacle lenses stems from the widely- accepted peripheral hyperopic defocus theory1, 2
- Sustained efficacy with no rebound effects3,4
- High patient acceptance5, tolerance5, and easy adaptation6
- Tested in children of different ethnicities and age groups4,6
- Improved outcomes in combination treatment with atropine7,8
- Awards and endorsements from credible associations, institutions, and international experts9-12
- Effective myopia management solution for children, with robust and quality evidence to support it3,4
- Over 4 million spectacle lenses sold worldwide in over 30 countries13
What can ECPs tell parents about the MiYOSMART 2-,3-,and 6-year studies on MiYOSMART?3,4,14
Here are the most important pieces of information you can offer parents when they bring their children in for their eye exams.
- On average, the efficacy is between 60-80% for AL in the 2-year RCT (at 6-,12-,18-,24-month).
- All participants who completed the 2-year RCT wearing MiYOSMART spectacle lenses showed their myopia progression was slowed down by 60% on average (measured by axial length).
- 9 out of 10 patients responded well to MiYOSMART spectacle lens (less than –1.00 D myopia progression in 2 years); and 1 out of 5 had no myopia progression in the 2-year RCT.
- It is beneficial to start wearing DIMS spectacle lenses at any time during childhood; however, it’s encouraged to start early.
- The myopia management treatment effect of MiYOSMART is sustained for 6 years with no rebound effect.
Frequently asked questions
What are the aspects of a highly effective myopia management solution?
Here are three very prominent aspects that can point to an effective myopia management solution: high efficacy (slowing down myopia progression by >50%), treatment effect being sustained over multiple years, and no rebound effect.
What are the benefits to evidence-based myopia management?
It builds confidence in patients, who can rely on their ECP to deliver solutions that have been extensively tested with proven outcomes. This drives patient satisfaction and loyalty, brings in new business, validates an ECP’s reputation, and increases practice revenue.
Does HOYA offer continuing education about myopia for ECPs?
Yes! HOYA Canada offers ECPs the Myopia Learning Centre. This CE platform is presented in collaboration with leading experts in myopia covering all topics related to myopia in children, the management and treatment thereof, and future consequences of myopia. ECPs can also find a collection of over 25 publications supporting our treatment's efficacy.
1 Nemeth J, Tapaszto B, Aclimandos WA, Kestelyn P, Jonas JB, De Faber JHN, et al. Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute. Eur J Ophthalmol. 2021;31(3):853-83.
2 Troilo D, Smith EL, 3rd, Nickla DL, Ashby R, Tkatchenko AV, Ostrin LA, et al. IMI - Report on Experimental Models of Emmetropization and Myopia. Invest Ophthalmol Vis Sci. 2019;60(3):M31-M88.
3 Lam CSY, Tang WC, Zhang HY, Lee PH, Tse DYY, Qi H, et al. Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. Sci Rep. 2023;13(1):5475.
4 Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-8.
5 Lu Y, Lin Z, Wen L, Gao W, Pan L, Li X, et al. The Adaptation and Acceptance of Defocus Incorporated Multiple Segment Lens for Chinese Children. Am J Ophthalmol. 2020;211:207-16.
6 McCullough S, Barr, H, Fulton, J, et al. 2-Year Multi-Site Observational Study of MiYOSMART myopia control spectacle lenses in UK children:1-year results (Abstract). ARVO 2023; 23-27 April 2023; New Orleans, LA, USA.
7 Nucci P, Lembo A, Schiavetti I, Shah R, Edgar DF, Evans BJW. A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS/atropine. PLoS One. 2023;18(2):e0281816.
8 Huang Z, Chen XF, He T, Tang Y, Du CX. Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia. Sci Rep. 2022;12(1):22311.
9 Silmo Paris. Winners 2020. 2020. Available from: https://en.silmoparis.com/SILMO-d-OR/SILMO-d-Or-Awards/ 2020-Winners (Last accessed: 20/07/2023).
10 Inventions Geneva. Winners of the exhibition’s grand prix. 2023. Available from: https://inventions-geneva.ch/en/ grand-prix-en/ (Last accessed: 20/07/2023).
11 World Society of Paediatric Ophthalmology and Strabismus (WSPOS). Myopia Consensus Statement 2023. 2023. Available from: https://www.wspos.org/swdcore/uploads/WSPOS-Myopia-Consensus-Statement-2023-1.pdf (Last accessed: 20/07/2023).
12 Jong M, Jonas JB, Wolffsohn JS, Berntsen DA, Cho P, Clarkson-Townsend D, et al. IMI 2021 Yearly Digest. Invest Ophthalmol Vis Sci. 2021;62(5):7.
13 Based on number of MiYOSMART spectacle lenses sold per HOYA sales data on file as of June 2022.
14 Lam CS, Tan WC, Lee PH, et al. Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. British Journey of Ophthalmology Published Online First: 17 March 2021. doi: 10.1136/bjophthalmol-2020-317664// The 3-year follow-up clinical study included 120 children aged 8-13 from the original 2-year RCT.